Skip to main content
OpenTrials
Completed

NCT Number: NCT06347627

Communicating Human Papillomavirus Vaccine With Japanese Parents and Caregivers With Daughters Aged 12-18

This study aims to comprehensively assess confidence in and acceptance of human papillomavirus (HPV) vaccines among Japanese parents and caregivers with daughters aged 12-18 and their decision-making process.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Age range

20 year and older

Sex eligibility

Female

Study type

Interventional

Phase

Not applicable

Primary location

London School of Hygiene and Tropical Medicine

London, United Kingdom

About this study

This study will implement an experiment as a sixteen-arm randomized controlled trial in an online survey environment. Before the experiment, participants, who are Japanese caregivers with daughters aged 12-18 who have not received an HPV vaccine, will first answer a pre-experiment survey. The survey will collect information on participants' socio-demographic data and key decision-making factors for HPV vaccine acceptance and confidence. Then, the study will randomly assign the participants to view one digital communication message using a 2 × 2 × 2 × 2 between-person factorial experiment on 'components of message.' The sixteen experimental messages will be developed based on real social media messages posted between November 2021 and April 2022, when the Japanese government prepared to reinstate an active recommendation of HPV vaccines for eligible girls after eight and a half years of suspension.

The sixteen messages will assess four factors: messenger, style, content, and misinformation. Each message will be similar except for one variable in consideration. The messenger component will be whether the message is from an individual or an organization. As individual messengers, the study will set a fictional male or female with common Japanese names who actively communicate about HPV vaccines. As organizational messengers, the study will use the existing accounts of the Ministry of Health, Labour and Welfare or the Japan Cancer Society or a fictional account of an anti-vaccine group. The style component will be whether the message conveys information through storytelling or scientific data. Messages will include personal stories for the storytelling style and statistics for the scientific data style. The content component will be whether the message conveys information about the effectiveness of the HPV vaccine in preventing diseases or the safety of the HPV vaccine. The contents will be built on both factual information and misconceptions about HPV vaccine safety and effectiveness that are often mentioned in the actual social media posts. The misinformation component will be whether the message conveys misinformation or factual information. The study will debrief all respondents exposed to misinformation after the survey.

Lastly, the study will collect data as a post-experiment survey to evaluate how an online message influenced caregivers' trust, confidence, and motivation to vaccinate.

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Female adult caregivers, older than 20, with daughters aged 12-18 who have received none or only one shot of HPV vaccine.

Exclusion criteria

  • Caregivers who do not agree to participate in survey, experiment, or both.
  • Caregivers with daughters who have already received two or more HPV vaccines.

Treatment and study plan

Group 1 (I x S x S x F)

Behavioral

Experimental message: Individual x Safety x Storytelling x Factual

Group 2 (O x S x S x F)

Behavioral

Experimental message: Organization x Safety x Storytelling x Factual

Group 3 (I x E x S x F)

Behavioral

Experimental message: Individual x Effectiveness x Storytelling x Factual

Group 4 (O x E x S x F)

Behavioral

Experimental message: Organization x Effectiveness x Storytelling x Factual

Group 5 (I x S x S x M)

Behavioral

Experimental message: Individual x Safety x Storytelling x Misinformation

Group 6 (O x S x S x M)

Behavioral

Experimental message: Organization x Safety x Storytelling x Misinformation

Group 7 (I x E x S x M)

Behavioral

Experimental message: Individual x Effectiveness x Storytelling x Misinformation

Group 8 (O x E x S x M)

Behavioral

Experimental message: Organization x Effectiveness x Storytelling x Misinformation

Group 9 (I x S x D x F)

Behavioral

Experimental message: Individual x Safety x Scientific data x Factual

Group 10 (O x S x D x F)

Behavioral

Experimental message: Organization x Safety x Scientific data x Factual

Group 11 (I x E x D x F)

Behavioral

Experimental message: Individual x Effectiveness x Scientific data x Factual

Group 12 (O x E x D x F)

Behavioral

Experimental message: Organization x Effectiveness x Scientific data x Factual

Group 13 (I x S x D x M)

Behavioral

Experimental message: Individual x Safety x Scientific data x Misinformation

Group 14 (O x S x D x M)

Behavioral

Experimental message: Organization x Safety x Scientific data x Misinformation

Group 15 (I x E x D x M)

Behavioral

Experimental message: Individual x Effectiveness x Scientific data x Misinformation

Group 16 (O x E x D x M)

Behavioral

Experimental message: Organization x Effectiveness x Scientific data x Misinformation

Primary outcomes

  1. Willingness to receive HPV vaccines for daughters

    Time frame: This experiment is expected to take 20-30 minutes to complete. The study will assess the outcome measure immediately after participants are exposed to the experimental messages.

    A degree of a change in willingness to receive HPV vaccines after viewing an experimental message will be scored on a 5-point scale. The options are 1) much less willing to get the HPV vaccine for my daughter, 2) somewhat less, 3) neither more or less, 4) somewhat more, and 5) much more, with higher scores indicating a better outcome.

Secondary outcomes

  1. Confidence in HPV vaccine safety

    Time frame: This experiment is expected to take 20-30 minutes to complete. The study will assess the outcome measure immediately after participants are exposed to the experimental messages.

    A degree of a change in confidence regarding HPV vaccine safety after viewing an experimental message will be scored on a 5-point scale. The options are 1) much less confident that the HPV vaccine is safe, 2) somewhat less, 3) neither more or less, 4) somewhat more, and 5) much more, with higher scores indicating a better outcome.

Sponsors and collaborators

Lead sponsor

The University of Hong Kong

Other

Collaborators

  • London School of Hygiene and Tropical Medicine
  • Nagasaki University

Registry information

Official study title

Communicating Human Papillomavirus Vaccine With Japanese Parents and Caregivers With Daughters Aged 12-18: a Mixed-methods Assessment of Acceptance of HPV Vaccine With Experiments on Communication Strategies

Important dates

Study start
2023
Primary completion
2024
Study completion
2024
First posted
Apr 4, 2024
Registry last updated
May 15, 2026

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.